Instalab
Icosapent ethyl · 4g/day · generic Vascepa®

Cut residual cardiovascular risk on top of your statin.

The only pure-EPA prescription FDA-approved to reduce cardiovascular events. In REDUCE-IT, statin patients with elevated triglycerides saw 25% fewer major cardiovascular events. Prescription, refills, and physician follow-up included.

25%Reduction in major CV events (REDUCE-IT)
20%Reduction in CV death (REDUCE-IT)
Pure EPANo DHA, no fish oil mixture
Icosapent Ethyl Prescription Review
Icosapent ethyl 1g · 2 capsules twice daily (4g total) · with meals
Licensed US physician review
12,000+ patients treated
Available in all 50 states
Ongoing lab follow-up
How it works

From questionnaire to first dose.

No clinic visits. A licensed physician reviews your labs and case, confirms eligibility for the FDA-approved CV indication, and writes the prescription. We handle refills and follow-up.

Step 1

2-minute questionnaire

Tell us about your triglyceride levels, current statin, cardiovascular history, and any other prior lipid medications. Upload a recent lipid panel if you have one.

Step 2

Physician review

A licensed physician confirms icosapent ethyl is appropriate (typically: established CVD or diabetes + risk factors, TG ≥ 150 on statin) and writes the prescription. Usually within 1 business day.

Step 3

Prescription sent to your pharmacy

Your physician routes the prescription to your pharmacy. Generic icosapent ethyl is now widely available since the 2021 generic launch.

Step 4

Lipid recheck at 3 months

Triglycerides drop within the first weeks. Recheck a lipid panel at 3 months to confirm response. CV event reduction is a long-term outcome, not something you feel.

Pricing

What you'll actually pay.

Two line items: Instalab Membership and the icosapent ethyl medication itself, dispensed by your pharmacy.

Instalab Membership

Physician oversight, lipid follow-up, prior authorization help, ongoing care

$—/mo

Icosapent ethyl 1g

Generic, dispensed by your pharmacy

Cash price$29–85/monthTypical pharmacy cash price (4g/day)
With insurance$10–60/monthTypical copay, varies by plan

Why pay a membership fee? Icosapent ethyl is a long-term CV-risk-reduction therapy that requires accurate diagnosis (elevated TG on statin, established CVD or T2D with risk factors) and lab follow-up. Membership covers the visits, prior authorization paperwork, and lipid follow-up. You pick up the prescription at your own pharmacy and pay them directly; labs are billed separately.

Will my insurance cover icosapent ethyl?

Most commercial and Medicare plans cover icosapent ethyl when prescribed for its FDA-approved CV-reduction indication: elevated triglycerides (≥150 mg/dL) on statin therapy, plus established cardiovascular disease or diabetes with two or more CV risk factors. Coverage often requires prior authorization. We file the paperwork. If insurance doesn't cover it, generic cash price has dropped significantly since 2021 — typically $35 to $80 per month at most pharmacies.

Why membership

Icosapent ethyl works. Coverage and follow-up take ongoing care.

Coverage depends on documenting the right indication, and the CV benefit only accrues over years of consistent use. Membership covers the physician oversight that gets you on it and keeps you on it.

  1. Week 1Day 1–5

    Physician review and prescription

    A licensed physician reviews your lipids, CV history, and statin therapy, confirms you meet the FDA-approved CV indication, and writes the prescription. We file prior authorization with your insurance in parallel.

  2. Week 2–4

    Pickup and first doses

    Pick up icosapent ethyl from your pharmacy. Take 2 capsules twice daily (4g total) with meals. Most patients tolerate it well; the most common side effect is mild reflux or fishy aftertaste.

  3. Month 3

    Lipid recheck

    Triglycerides drop within the first weeks. Recheck a lipid panel at month 3 to confirm response. LDL does not change much — icosapent ethyl targets TG and CV outcomes, not LDL.

  4. OngoingMonth 6+

    Renewals and ongoing care

    CV event reduction is a long-term benefit that only accrues with consistent daily dosing. We keep your prescription active and handle any insurance re-authorization. Lifestyle and statin therapy stay foundational; icosapent ethyl is the add-on.

Without membership

Schedule a cardiology or PCP visit. Hope they know the REDUCE-IT criteria. Hope they file the prior auth. Get denied. Try again next year.

With Instalab

2-minute questionnaire. Physician review within 1 business day. Prior authorization filed. Refills handled. Lipid follow-up built in.

About the medication

Two capsules, twice a day. With meals.

Icosapent ethyl is a prescription pure-EPA omega-3 ester. Unlike OTC fish oil, it contains only EPA (no DHA, no impurities). The dosing is 2 grams twice daily — 4 grams total per day.

  • Two capsules, twice daily2g morning, 2g evening, both with meals to improve absorption. 4 grams total per day is the FDA-approved CV-reduction dose.
  • Different from OTC fish oilOTC fish oil is a mix of EPA + DHA plus other compounds. Icosapent ethyl is pharmaceutical-grade pure EPA. The CV outcomes data are specific to this molecule — they do not translate to OTC fish oil supplements.
  • Lab recheck at 3 monthsRecheck triglycerides at 3 months to confirm response. LDL does not change meaningfully on icosapent ethyl; CV events are the primary endpoint.
  • Ongoing supportOur care team is a message away. Reach out for refills, side effects, or prior authorization issues.
Why icosapent ethyl

The first non-statin add-on to reduce CV events on top of a statin.

Patients on statins can still have elevated triglycerides and significant residual cardiovascular risk. Icosapent ethyl was developed specifically to target that residual risk. The REDUCE-IT trial — published in NEJM in 2018 — randomized over 8,000 high-risk patients already on statins to icosapent ethyl or mineral oil placebo. The result: a 25% reduction in major cardiovascular events and a 20% reduction in cardiovascular death. It remains one of the most striking outcome trials in lipid therapy of the past two decades.

  • 25% reduction in major CV eventsAcross REDUCE-IT, icosapent ethyl 4g/day cut the composite of cardiovascular death, MI, stroke, coronary revascularization, and unstable angina by 25% versus placebo, on top of statin therapy.
  • Targets residual riskStatins lower LDL. Icosapent ethyl targets the inflammation, triglyceride metabolism, and arrhythmic pathways that statins do not address. The two therapies are complementary, not redundant.
  • Pure EPA, not fish oilOTC fish oil supplements do not have this evidence. Trials of mixed EPA+DHA preparations have been negative. Whatever the precise mechanism, it appears to be specific to high-dose pure EPA in patients with elevated triglycerides.

The REDUCE-IT trial

Published in NEJM in 2018, REDUCE-IT randomized 8,179 patients on statins with elevated triglycerides (135–499 mg/dL) and either established cardiovascular disease or diabetes plus risk factors to icosapent ethyl 4g/day or placebo. Over a median 4.9 years, icosapent ethyl reduced the primary composite (CV death, MI, stroke, revascularization, unstable angina) by 25%, with a 20% reduction in cardiovascular death. The result drove FDA approval of the CV-reduction indication in 2019 and the AHA/ACC guideline endorsement that followed.

8,179
Patients on statins randomized
25%
Reduction in major CV events
4.9 yrs
Median follow-up

Icosapent ethyl is a prescription medicine. Important safety information applies. Most patients tolerate it well. The notable safety signals are atrial fibrillation and a small increase in bleeding risk, both observed in REDUCE-IT.

Ready when you are

Cut residual CV risk on top of your statin.

Answer the questionnaire and upload a recent lipid panel. A physician reviews your case and, if icosapent ethyl is appropriate, prescribes it. We file prior authorization and handle refills.

No commitment to treatment.